Skip to content
Clinical Trials – home

Wojewodzki Specjalistyczny Szpital Im Dr Wl Bieganskiego

Verified siteinfo

Poland Ul. Gen. Karola Kniaziewicza 1/5, 91-347 Lodz, Poland

  • 7 trials recruiting
  • Arteriosclerosis · HIV infection · Pulmonary arterial hypertension
  • Adults and children

About Specializations

Wojewodzki Specjalistyczny Szpital Im Dr Wl Bieganskiego in Lodz, Poland specialises in clinical trials of conditions such as Arteriosclerosis, HIV infection, Pulmonary arterial hypertension, Pulmonary hypertension, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases and Metabolic Risk

At Wojewodzki Specjalistyczny Szpital Im Dr Wl Bieganskiego in Lodz, research in cardiovascular diseases focuses on major conditions such as acute coronary syndromes, heart failure, and hypertrophic cardiomyopathy, along with high-risk lipid disorders.

  • Studies are assessing new approaches to lower cardiovascular event risk and improve outcomes after heart attack or in people at elevated risk.
  • Trials also examine treatments for heart failure with reduced ejection fraction and symptom relief in hypertrophic cardiomyopathy.
  • Another key area is familial hypercholesterolemia and elevated lipoprotein(a), with the goal of better prevention of future heart disease.

Overall, this site is contributing to studies that test whether newer therapies can reduce complications, improve quality of life, and strengthen long-term cardiovascular protection.

Pulmonary Hypertension and Respiratory Tract Diseases

The hospital has a strong program in pulmonary hypertension and related respiratory tract diseases, including pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, and combined postcapillary and precapillary pulmonary hypertension.

  • Research is evaluating treatments that may improve pulmonary vascular resistance and exercise capacity in people with advanced lung-circulation disorders.
  • Some trials focus on patients with pulmonary hypertension linked to heart failure with preserved ejection fraction, aiming to better control symptoms and hemodynamics.
  • The site is also involved in studies of therapies added to existing care to test safety, tolerability, and overall treatment benefit.

This area reflects an active effort to find more effective options for serious breathing and circulation problems that can be difficult to treat.

Immune System Diseases and Skin Disorders

Within dermatology, the department studies immune system diseases and skin and connective tissue diseases, especially atopic dermatitis and moderate to severe plaque psoriasis.

  • These trials are designed to evaluate new therapies for reducing skin inflammation and improving day-to-day comfort.
  • Some research includes children and adolescents, helping determine whether treatments can be effective and well tolerated in younger patients.
  • The work also supports better understanding of how targeted immune treatments may help control chronic skin disease.

As a dermatology-focused unit, Oddzial Dermatologii, Dermatologii Dzieciecej i Onkologicznej contributes to studies aimed at improving care for both common and more severe inflammatory skin conditions.

Virus Diseases and HIV Research

The site participates in clinical trials on virus diseases, with a particular focus on HIV and HIV-1 infection, including studies in both treatment-naive and virologically suppressed adults.

  • Research is testing whether newer antiviral regimens can provide effective control of HIV while supporting simpler treatment options.
  • Some studies compare switch strategies in people already doing well on therapy, with the goal of maintaining viral suppression.
  • These trials help evaluate convenience, durability of response, and overall treatment effectiveness for long-term HIV care.

This work broadens the site’s infectious disease portfolio by contributing to efforts that improve ongoing management of chronic viral infection.

Inflammation-Driven Cardiometabolic Prevention

Several trials at this Polish hospital are exploring whether targeting inflammation and lipid-related risk can prevent serious events in people with established or emerging cardiovascular disease.

  • Key studies include patients after myocardial infarction or those with high baseline risk for future heart events.
  • Researchers are examining therapies intended to reduce recurrent complications and improve long-term prevention.
  • This work combines interest in cardiology, lipid disorders, and broader metabolic disease risk management.

By focusing on prevention as well as treatment, the site supports research aimed at lowering the burden of major heart and vascular events.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Gen. Karola Kniaziewicza 1/591-347 LodzPoland
Recruiting now
7 trials
Conditions studied
19
Partner status
Verified site

More sites in LodzPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

35 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Sponsor:Novo Nordisk A/S

Study on Tozorakimab for Patients Hospitalized with Severe Viral Lung Infections Needing Oxygen

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tozorakimab
  • Sponsor:AstraZeneca AB

A study to evaluate the safety and effectiveness of IKT-001 compared to a placebo in adults with pulmonary arterial hypertension.

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years

A study to evaluate the effectiveness and safety of REGN13335 in adults with pulmonary arterial hypertension

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B
  • Sponsor:Regeneron Pharmaceuticals Inc.

HIV infection

Recruiting

A study testing VH4524184 with emtricitabine and tenofovir alafenamide compared to dolutegravir and lamivudine in adults with HIV-1 who have not received treatment before

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dolutegravir Sodium
  • Sponsor:Viiv Healthcare UK Limited

Study on Inclisiran, Alirocumab, and Rosuvastatin for Children with Familial Hypercholesterolemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Alirocumab
  • Sponsor:Medical University Of Lodz

Long-term Safety Study of Tadalafil and Macitentan for Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Macitentan
  • Sponsor:Actelion Pharmaceuticals Ltd.

Aortic valve stenosis

Not yet recruiting

A Phase 2b/3 Randomized Double‑Blind Study of Ataciguat to Slow Disease Progression in Adults with Moderate Calcific Aortic Valve Stenosis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Kardigan Inc.

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

HIV infection

Not yet recruiting

Study of Weekly Oral GS-1720 and GS-4182 for People with HIV-1 Who Are Virologically Suppressed

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Gilead Sciences Inc.

HIV infection

Not yet recruiting

Study on Doravirine and Islatravir for People with HIV-1 Previously Treated with the Same Drug Combination

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Doravirine
  • Sponsor:Merck Sharp & Dohme LLC

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.